Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma

NCT05096481 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.

NCT NCT05096481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05096481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma
Lead sponsor
Nationwide Children's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
July 18, 2024
Completion date
June 15, 2030
Enrollment
120 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, high grade glioma, recurrent medulloblastoma